CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 2.38: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.23BCNY333.53M · vs all stocks (USD)
Revenue (TTM)
423.20MCNY63.20M · vs all stocks (USD)
Profit Margin
-56.97%Beta
0.1370xvs all stocks
52-Week Change
-24.20%vs all stocks
Market Capitalization
2.23BCNY333.53M · vs all stocks (USD)
Enterprise Value
2.16BCNY323.09M · vs all stocks (USD)
Price to Sales (TTM)
4.93xPrice to Book (MRQ)
1.54xEnterprise to Revenue
5.11xEnterprise to EBITDA
-96.18xGross Margin
50.80%Profit Margin
-56.97%Operating Margin
-22.63%Return on Assets (TTM)
-2.68%Return on Equity (TTM)
-16.16%Revenue (TTM)
423.20MCNY63.20M · vs all stocks (USD)
Revenue per Share (TTM)
1.10CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-27.10%Gross Profit (TTM)
156.87MCNY23.43M · vs all stocks (USD)
EBITDA (TTM)
92.22MCNY13.77M · vs all stocks (USD)
Net Income (TTM)
-241.08MCNY-36.00M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
250.50%Operating Cash Flow (TTM)
-5.61MCNY-837.98K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-90.92MCNY-13.58M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
31.29KCNYFY2025 · Dec 31, 2025Revenue
462.78MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
250.08MCNYFY2025 · Dec 31, 2025Gross Profit
212.70MCNYFY2025 · Dec 31, 2025Operating Income
-6.09MCNY-908.78K · vs all stocks (USD)
Pre-tax Income
-239.93MCNYFY2025 · Dec 31, 2025Income Tax Expense
-1.21MCNYFY2025 · Dec 31, 2025Net Income
-238.73MCNYFY2025 · Dec 31, 2025EBIT
-231.99MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
92.22MCNYFY2025 · Dec 31, 2025Research & Development
25.20MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
117.79MCNYFY2025 · Dec 31, 2025Other Operating Expenses
9.84MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
247.77KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
7.94MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.6400CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.6400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
373.00MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
373.00MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-238.73MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
4.44KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-235.96MCNYFY2025 · Dec 31, 2025Free Cash Flow
-330.05MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
112.18MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-238.73MCNYFY2025 · Dec 31, 2025Other Non-cash Items
10.67MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
6.54MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-14.44MCNYFY2025 · Dec 31, 2025Capital Expenditures
-94.09MCNYFY2025 · Dec 31, 2025Net Acquisitions
-6.15MCNYFY2025 · Dec 31, 2025Sale of Investments
812.50KCNYFY2025 · Dec 31, 2025Other Investing Activity
31.16MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-68.26MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
209.40MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-133.65MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-7.94MCNYFY2025 · Dec 31, 2025Other Financing Charges
-15.09MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
52.72MCNYFY2025 · Dec 31, 2025Shares Outstanding
374.13MSharesUpdated Sep 22, 2026Float Shares
206.93MSharesUpdated Sep 22, 2026% Held by Insiders
48.48%vs all stocks
% Held by Institutions
2.39%vs all stocks
Total Cash (MRQ)
203.64MCNY30.41M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5440CNYUpdated Sep 22, 2026Total Debt (MRQ)
279.57MCNY41.75M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2040xCurrent Ratio (MRQ)
0.9360xBook Value per Share (MRQ)
3.61CNYUpdated Sep 22, 2026Total Assets
1.87BCNY279.58M · vs all stocks (USD)
Total Current Assets
368.18MCNYFY2025 · Dec 31, 2025Total Liabilities
521.04MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.50BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
129.74MCNYFY2025 · Dec 31, 2025Total Current Liabilities
391.30MCNYFY2025 · Dec 31, 2025Cash
104.26MCNYFY2025 · Dec 31, 2025Cash Equivalents
7.92MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
112.18MCNYFY2025 · Dec 31, 2025Other Short-term Investments
112.22MCNYFY2025 · Dec 31, 2025Accounts Receivable
26.65MCNYFY2025 · Dec 31, 2025Inventory
76.72MCNYFY2025 · Dec 31, 2025Accounts Payable
120.19MCNYFY2025 · Dec 31, 2025Short-term Debt
177.88MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.12MCNYFY2025 · Dec 31, 2025Long-term Debt
123.07MCNYFY2025 · Dec 31, 2025Common Stock (Book)
374.13MCNYFY2025 · Dec 31, 2025Retained Earnings
-26.72MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.35BCNY201.78M · vs all stocks (USD)
Treasury Stock
6.77MCNYFY2025 · Dec 31, 202552-Week Low
4.55CNYUpdated Sep 22, 202652-Week High
8.81CNYUpdated Sep 22, 202652-Week Change
-24.20%vs all stocks
Beta
0.1370xvs all stocks
50-Day MA
5.49CNYUpdated Sep 22, 2026200-Day MA
6.42CNYUpdated Sep 22, 2026Avg 10-Day Volume
6.03MSharesUpdated Sep 22, 2026Avg 30-Day Volume
7.27MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-0.6500CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.51Profit Margin: -0.57
Financial Health
Altman Z-Score 2.38: grey zoneSignificant
Altman Z-Score: 2.38
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanxi C&Y Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Benitec Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xinguang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cuorips Inc.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Guangji Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Newron Pharmaceuticals SpA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Il Dong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jilin Jian Yisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule